Literature DB >> 1911739

Dose ranging study of the effects of cholecystokinin in healthy volunteers.

J Bradwejn1, D Koszycki, M Bourin.   

Abstract

The authors determined whether response to cholecystokinin-tetrapeptide (CCK-4) was dose-dependent. Healthy volunteers (n = 36) received double-blind injections of either 9 micrograms, 25 micrograms, or 50 micrograms of CCK-4 and placebo in a randomized sequence of injection. Significant dose-related differences were found for the number of symptoms, sum intensity of symptoms and the time until onset of symptoms, but not for the duration of symptoms. The incidence of panic attacks with CCK-4 was 11%, 17% and 47% for the 9 micrograms, 25 micrograms and 50 micrograms dose, respectively. None of the controls panicked with placebo injections. These results support the notion of a dose-dependent effect of CCK-4-induced panic symptoms. Implications of these findings in the neurobiology of panic attacks are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911739      PMCID: PMC1188299     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  18 in total

1.  Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat.

Authors:  A Bouthillier; C De Montigny
Journal:  Eur J Pharmacol       Date:  1988-06-22       Impact factor: 4.432

2.  Neurobiology of panic disorder.

Authors:  C D Karkanias; G A Block; S Reines; J Bradwejn
Journal:  Am J Psychiatry       Date:  1989-10       Impact factor: 18.112

3.  Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

Authors:  C de Montigny
Journal:  Arch Gen Psychiatry       Date:  1989-06

4.  A cognitive approach to panic.

Authors:  D M Clark
Journal:  Behav Res Ther       Date:  1986

5.  Clinical and neuroendocrine studies with cholecystokinin peptides.

Authors:  N P Nair; D Bloom; S Lal; G Debonnel; G Schwartz; S Mosticyan
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

6.  Two brain cholecystokinin receptors: implications for behavioral actions.

Authors:  T H Moran; P H Robinson; M S Goldrich; P R McHugh
Journal:  Brain Res       Date:  1986-01-01       Impact factor: 3.252

7.  Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder.

Authors:  D J Nutt; P Glue; C Lawson; S Wilson
Journal:  Arch Gen Psychiatry       Date:  1990-10

8.  Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones.

Authors:  J Bradwejn; C de Montigny
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

9.  Endocrine, cardiovascular, and behavioral effects of intravenous protirelin in patients with panic disorder.

Authors:  M B Stein; T W Uhde
Journal:  Arch Gen Psychiatry       Date:  1991-02

10.  Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.

Authors:  J Hughes; P Boden; B Costall; A Domeney; E Kelly; D C Horwell; J C Hunter; R D Pinnock; G N Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

View more
  8 in total

Review 1.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

Review 2.  Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.

Authors:  Peter Zwanzger; Rainer Rupprecht
Journal:  J Psychiatry Neurosci       Date:  2005-05       Impact factor: 6.186

3.  The neuropeptide Drosulfakinin regulates social isolation-induced aggression in Drosophila.

Authors:  Pavan Agrawal; Damian Kao; Phuong Chung; Loren L Looger
Journal:  J Exp Biol       Date:  2020-01-29       Impact factor: 3.312

Review 4.  Neurobiological investigations into the role of cholecystokinin in panic disorder.

Authors:  J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

5.  Human models as tools in the development of psychotropic drugs.

Authors:  Christian Gilles; Thérèse Schunck; Gilles Erb; Izzie Jacques Namer; Yann Hodé; Jean-François Nedelec; Peter Boeijinga; Remy Luthringer; Jean-Paul Mâcher
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

Review 6.  Experimental panic provocation in healthy man-a translational role in anti-panic drug development?

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

7.  Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.

Authors:  Agorastos Agorastos; Michael Kellner; Oliver Stiedl; Christoph Muhtz; Klaus Wiedemann; Cüneyt Demiralay
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-11       Impact factor: 5.176

Review 8.  Can Interoception Improve the Pragmatic Search for Biomarkers in Psychiatry?

Authors:  Sahib S Khalsa; Rachel C Lapidus
Journal:  Front Psychiatry       Date:  2016-07-25       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.